MAM
30% online consum30% online consumers turn to cable TV websites for news: JupiterResearchers turn to cable TV websites for news: JupiterResearch
Newsletters Email Story Print Comment
Indiantelevision.com’s Media, Advertising, Marketing Watch
30% online consumers turn to cable TV websites for news: JupiterResearch
Indiantelevision.com Team
(21 December 2005 8:00 pm)
MUMBAI: Cable television and portal websites are well-positioned to dominate the online news market. A study done by JupiterResearch revealed that while most online consumers still get their national and international news from television, 30 per cent of online consumers turn to cable TV news sites for their national and international news versus 29 per cent for print newspapers.
JupiterResearch’s report titled “The Future of News,” discusses this issue, as well as who the major players will be and what news organisations must do to succeed within the changing media landscape.
News websites will need to make some key changes over the next one to two years in order to remain competitive. Among these changes are to embrace the “grammar of connectedness”, the features that link web publishers to each other and to their readers more closely, such as syndication, aggregation, outside-the-site linking and feedback.
“Web news organisations must think of their fundamental product as the story, and not the site. A website is not experienced as a coherent product, but rather as individual pages, each of which serves as an entry point. Also, far too few web news publishers have adopted the emerging “grammar of connectedness” that will drive growth on the web in the next five years,” said ,” said JupiterResearch analyst Barry Parr.
The popularity of web content over offline newspapers means newspapers must adapt to meet the needs of their changing audiences. Newspapers are advised to look to the web not just to retain their older, offline user base, but to attract a younger – and in many cases, entirely different – group of users as well. Taking a predominantly local approach is another necessity for newspapers, since television and cable TV news sites already attract the most national and international news seekers.
“It is no surprise that newspaper circulation is declining. The internet has been eating away at the time consumers spend with other media. And now it is actually dictating an entirely new set of news habits and expectations,” said JupiterResearch senior vice president of research David Schatsky.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
